COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Use of Dexamethasone in Uterine Artery Embolization

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02056717
Recruitment Status : Completed
First Posted : February 6, 2014
Last Update Posted : April 17, 2015
Information provided by (Responsible Party):
So Yeon Kim, Severance Hospital

Brief Summary:
The primary purpose of this study is to investigate the effects of dexamethasone on inflammatory reactions after uterine artery embolization. The secondary purpose of this study it to investigate the effects of dexamethasone on postembolization syndrome (severe pain, nasea and vomiting).

Condition or disease Intervention/treatment Phase
Uterine Myoma Adenomyosis Drug: Dexamethasone Drug: Normal saline Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Effect of Dexamethasone on Inflammatory Response After Uterine Artery Embolization
Study Start Date : April 2014
Actual Primary Completion Date : April 2015
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Dexamethasone group Drug: Dexamethasone
Administration of dexamethasone 10 mg IV 1 h before UAE

Placebo Comparator: Control group Drug: Normal saline
Administration of normal saline 2 mL IV 1 h before UAE

Primary Outcome Measures :
  1. Inflammatory reactions [ Time Frame: 24 hours ]
    CRP, WBC, neutrophil (%), cortisol : pre-UAE, post-UAE 12 h, post-UAE-24 h IL-6 : pre-UAE, post-UAE-24 h

Secondary Outcome Measures :
  1. Pain [ Time Frame: 24 hours ]
    Immediately after UAE, post-UAE 1, 2, 4, 6, 8, 12, 24 h

  2. Nausea and vomiting [ Time Frame: 24 hours ]
    Immediately after UAE, post-UAE 1, 2, 4, 6, 8, 12, 24 h

  3. Sucessful rate at 3 month after UAE [ Time Frame: 3 month ]
    Utrerine volume and complete necrosis incidence

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Uterine artery embolization due to multiple myoma or adenomyosis

Exclusion Criteria:

  • Diabetic mellitus
  • Steroid administration
  • Liver or kidney dysfuntion
  • High baseline CRP or leukocytosis (>11,000/μL )
  • Drug allergy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02056717

Layout table for location information
Korea, Republic of
Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei University College of Medicine
Seoul, Korea, Republic of
Sponsors and Collaborators
Severance Hospital
Layout table for additonal information
Responsible Party: So Yeon Kim, Assistant professor, Severance Hospital Identifier: NCT02056717    
Other Study ID Numbers: 4-2013-0863
First Posted: February 6, 2014    Key Record Dates
Last Update Posted: April 17, 2015
Last Verified: April 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Diseases
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents